SCYX vs. GNLX, FTLF, TARA, KRRO, SKYE, ACTU, ALTS, ATOS, CLLS, and BHST
Should you be buying SCYNEXIS stock or one of its competitors? The main competitors of SCYNEXIS include Genelux (GNLX), FitLife Brands (FTLF), Protara Therapeutics (TARA), Korro Bio (KRRO), Skye Bioscience (SKYE), Actuate Therapeutics (ACTU), ALT5 Sigma (ALTS), Atossa Genetics (ATOS), Cellectis (CLLS), and BioHarvest Sciences (BHST). These companies are all part of the "pharmaceutical products" industry.
SCYNEXIS vs. Its Competitors
SCYNEXIS (NASDAQ:SCYX) and Genelux (NASDAQ:GNLX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.
SCYNEXIS has a beta of 1.57, suggesting that its stock price is 57% more volatile than the S&P 500. Comparatively, Genelux has a beta of -0.34, suggesting that its stock price is 134% less volatile than the S&P 500.
Genelux has a consensus price target of $17.75, suggesting a potential upside of 433.03%. Given Genelux's stronger consensus rating and higher probable upside, analysts plainly believe Genelux is more favorable than SCYNEXIS.
SCYNEXIS has higher revenue and earnings than Genelux. Genelux is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks.
Genelux has a net margin of 0.00% compared to SCYNEXIS's net margin of -1,030.04%. SCYNEXIS's return on equity of -53.47% beat Genelux's return on equity.
54.4% of SCYNEXIS shares are owned by institutional investors. Comparatively, 37.3% of Genelux shares are owned by institutional investors. 4.9% of SCYNEXIS shares are owned by insiders. Comparatively, 9.3% of Genelux shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
In the previous week, Genelux had 3 more articles in the media than SCYNEXIS. MarketBeat recorded 3 mentions for Genelux and 0 mentions for SCYNEXIS. SCYNEXIS's average media sentiment score of 1.87 beat Genelux's score of 0.91 indicating that SCYNEXIS is being referred to more favorably in the media.
Summary
SCYNEXIS and Genelux tied by winning 8 of the 16 factors compared between the two stocks.
Get SCYNEXIS News Delivered to You Automatically
Sign up to receive the latest news and ratings for SCYX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SCYX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
SCYNEXIS Competitors List
Related Companies and Tools
This page (NASDAQ:SCYX) was last updated on 7/18/2025 by MarketBeat.com Staff